Hepatocellular carcinoma
Conditions
Interventions
Test group:Refined DEB-TACE embolization therapy
Sponsors
People's Hospital of Henan Province
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients who meet the clinical diagnostic criteria of the 2024 edition of the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer" or have been diagnosed with primary liver cancer through pathology, have at least one measurable tumor lesion, and are not suitable/refuse surgical resection, liver transplantation, and ablation treatment; 2. Gender is not limited, age >= 18 years old; 3. Child Pugh A-B grade; 4. ECOG score 0-1 points; 5. No serious complications; 6. The patient's expected survival period exceeds 3 months; 7. Agree to participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Giant liver tumor (>= 60% liver volume); 2. Diffuse liver cancer patients; 3. Unstable systemic diseases or uncontrolled infections; 4. Difficult to correct renal function and coagulation dysfunction; 5. Any unstable condition or potential threat to patient safety and their compliance with the study; 6. Those who require termination of treatment due to any adverse events; 7. The patient or legal representative requests to stop treatment; 8. Due to various reasons, the treatment plan cannot be completed, or the patient is lost to follow-up; 9. The researchers believe that other patients who are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Progression-free survival;Overall survival;Safety; | — |
Countries
China
Contacts
Public ContactGuangshao Cao
People's Hospital of Henan Province
Outcome results
None listed